Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial.

[1]  David S. Yee,et al.  Role of prostate specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. , 2011, The Journal of urology.

[2]  Kirsten L. Greene,et al.  Outcomes of active surveillance for men with intermediate-risk prostate cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Jack Hadley,et al.  Comparative effectiveness of prostate cancer treatments: evaluating statistical adjustments for confounding in observational data. , 2010, Journal of the National Cancer Institute.

[4]  Susan T. Stewart,et al.  Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. , 2010, JAMA.

[5]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[6]  L. Klotz,et al.  Active surveillance for prostate cancer: patient selection and management. , 2010, Current oncology.

[7]  V. Laudone,et al.  Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. , 2010, The Journal of urology.

[8]  D. Dearnaley,et al.  A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. , 2009, European urology.

[9]  Michael Seitz,et al.  Insignificant prostate cancer and active surveillance: from definition to clinical implications. , 2009, European urology.

[10]  Andrew J Vickers,et al.  The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. , 2009, The Lancet. Oncology.

[11]  L. Holmberg,et al.  Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. , 2008, Journal of the National Cancer Institute.

[12]  M. Cooperberg,et al.  Active surveillance for the management of prostate cancer in a contemporary cohort , 2008, Cancer.

[13]  T. Wilt,et al.  Systematic Review: Comparative Effectiveness and Harms of Treatments for Clinically Localized Prostate Cancer , 2008, Annals of Internal Medicine.

[14]  E. Metter,et al.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience. , 2007, The Journal of urology.

[15]  E. Metter,et al.  Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience , 2007 .

[16]  M. Kattan,et al.  The surgical learning curve for prostate cancer control after radical prostatectomy. , 2007, Journal of the National Cancer Institute.

[17]  P. Ravdin,et al.  A decision aid to assist in adjuvant therapy choices for breast cancer , 2006, Psycho-oncology.

[18]  James A Hanley,et al.  Prostate cancer and the Will Rogers phenomenon. , 2005, Journal of the National Cancer Institute.

[19]  M. Cooperberg,et al.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). , 2003, The Journal of urology.

[20]  Les M Irwig,et al.  An evidence based approach to individualising treatment , 1995, BMJ.

[21]  Liying Zhang,et al.  Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.